<DOC>
	<DOCNO>NCT00006347</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient relapse refractory small cell lung cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose limit toxicity maximum tolerate dose yttrium Y 90 anti-CEA monoclonal antibody MN-14 patient relapse refractory small cell lung cancer . - Determine dosimetric pharmacokinetic property treatment regimen blood , normal organ , tumor patient . - Determine stability complexation circulate carcinoembryonic antigen radioantibody plasma patient . - Determine antibody response patient treat regimen . - Determine antitumor effect treatment regimen patient . OUTLINE : This dose escalation study yttrium Y 90 anti-CEA monoclonal antibody MN-14 ( 90Y-hMN-14 ) . Patients stratify accord prior radiotherapy ( yes v ) . Patients undergo pretherapy image indium In 111 anti-CEA monoclonal antibody MN-14 IV 30-40 minute day -7 -6 follow external scintigraphy day -7 -6 0 . Patients show positive localization least one documented tumor site receive 90Y-hMN-14 IV 30-40 minute day 0 . Cohorts 3-6 patient receive escalate dos 90Y-hMN-14 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose limit toxicity . Patients follow 2 , 4 , 8 , 12 week ; every 3 month 2 year ; every 6 month 3 year . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 10-14 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer ( SCLC ) Must receive least one prior course standard chemotherapy , indicate , 6,900 cGy thoracic radiotherapy Patients receive prior radiotherapy must show evidence progressive disease Patients receive prior radiotherapy primary tumor must show evidence stable progressive disease Measurable disease Must evidence carcinoembryonic antigen ( CEA ) production expression document one following : Serum CEA least 10 ng/mL Positive immunohistology either primary tumor metastasis CEA specific monoclonal antibody Must unilateral bone marrow biopsy le 25 % tumor involvement No known , active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 mg/dL AST great 2 time upper limit normal ( ULN ) No hepatitis B C No serious liver abnormality Renal : Creatinine great 1.5 time ULN No urinary incontinence Cardiovascular : Ejection fraction least 50 % Pulmonary : FEV_1 FVC least 60 % DLCO least 50 % predict Other : No severe anorexia , nausea , vomit No significant medical problem No prisoner No reactivity humanize MN14 ( patient prior exposure chimeric humanize antibody ) HIV negative No active HIVrelated disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month follow study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No concurrent growth factor ( e.g. , filgrastim [ GCSF ] ) Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No prior high dose chemotherapy stem cell transplantation Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Prior radiotherapy le 30 % red marrow ( include standard chest xray limit stage SCLC ) allow Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>